TMCnet News
Research and Markets: The Global Pharmaceuticals Market Generated Total Revenues of $644,204.4 Million In 2009DUBLIN --(Business Wire)-- Research and Markets(http://www.researchandmarkets.com/research/6af23e/pharmaceuticals_g) has announced the addition of the "Pharmaceuticals: Global Industry Overview" report to their offering. The Pharmaceuticals: Global Industry Overview is an essential resource for top-level data and analysis covering the Global Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, Life Sciences Tools & Services, OTC Pharmaceuticals, Pharmaceuticals and Pharmaceuticals, Biotechnology & Life Sciences Scope of the Report Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, Life Sciences Tools & Services, OTC Pharmaceuticals, Pharmaceuticals and Pharmaceuticals, Biotechnology & Life Sciences Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies Incorporates in-depth five forces competitive environment analysis and scorecards Includes five-year forecasts for Biotechnology, Generics, Life Sciences Tools & Services, OTC Pharmaceuticals, Pharmaceuticals and Pharmaceuticals, Biotechnology & Life Sciences Highlights The global pharmaceuticals market generated total revenues of $644,204.4 million in 2009, representing a compound annual growth rate (CAGR) of 4.3% for the period spanning 2005-2009. The global OTC pharmaceuticals market generated total revenues of $99.4 billion in 2008, representing a compound annual growth rate (CAGR) of 4% for the period spanning 2004-2008. The global biotechnology market generated total revenues of $227.1 billion in 2008, representing a compound annual growth rate (CAGR) of 11.8% for the period spanning 2004-2008. The global generics market generated total revenues of $191.8 billion in 2008, representing a compound annual growth rate (CAGR) of 11.6% for the period spanning 2004-2008. The global life sciences tools & services market generated total revenues of $37.8 billion in 2008, representing a compound annual growth rate (CAGR) of 17.9% for the period spanning 2004-2008. The global pharmaceuticals, biotechnology, and life sciences industry group generated total revenues of $917 billion in 2008, representing a compound annual growth rate (CAGR) of 6.8% for the period spanning 2004-2008. Why you should buy this report Spot future trends and developments Inform your business decisions Add weight to presentations and marketing materials Save time carrying out entry-level research Key Topics Covered: CHAPTER 1 GLOBAL BIOTECHNOLOGY CHAPTER 2 GLOBAL GENERICS CHAPTER 3 GLOBAL OTC PHARMACEUTICALS CHAPTER 4 GLOBAL PHARMACEUTICALS CHAPTER 5 APPENDIX LIST OF TABLES LIST OF FIGURES Sample: The following information is extracted from various sections of the report. PHARMACEUTICALS IN BELGIUM Market Overview Research Highlights The Belgian pharmaceuticals market reached a value of $3.2 billion in 2003. During the next five years, the market is expected to grow at a CAGR of 5.3%. Although there are domestic companies operating within the Belgian market, the largest proportion of revenues is generated by a relatively small number of multinational pharmaceutical corporations. Market Analysis The Belgian pharmaceuticals market reached a value of $3.2 billion in 2003, having grown with a compound annual growth rate (CAGR) of 5.7% in the 1999-2003 period. This growth was slightly lower than that of the European market itself, leading to the Belgian market's regional share decreasing by 0 percentage points between 1999-2003, accounting for 2.9% of the European market by the end of this period. The leading revenue source for the Belgian pharmaceuticals market in 2003 was the cardiovascular sector, which accounted for 24.1% of the market's value. In value terms, this sector was worth $777.5 million in 2003. The central nervous system sector generated the second largest revenues in 2003, reaching a value of $561 million, equivalent to 17.4% of the market's value. During the next five years, the market is expected to experience a minor decline in growth rates. By 2008, the market is forecast to reach a value of $4.2 billion, which equates to a CAGR of 5 3% in the 2003-2008 period, lower than the predicted overall European growth rate. PHARMACEUTICALS IN GERMANY Market Value In 2003 the German pharmaceuticals market grew by 8.2% to reach a value of $23.8 billion. In the 1999-2003 period the compound annual growth rate of the market was 6.7%. The annual market growth rose from its low of 4.7% in 2000 to a high of 8.2% in 2003. Tables(provided in full report) Germany Pharmaceuticals Market Value: $ billion, 1999-2003 Germany Pharmaceuticals Market Value: $ billion, 1999-2003 PHARMACEUTICALS IN THE UNITED KINGDOM Merck & Co., Inc. Strengths Spin-off of Medco Health In August 2003, Merck completed the spin-off of Medco Health, its pharmacy benefits management subsidiary. This split will allow Merck to focus on its core ethicals business. Hence, the company will be able to use funds that used to be invested in Medco Health to strengthen its pharmaceuticals business. Compared to peers such as Pfizer, GlaxoSmithKline and Aventis, Merck's expenditure on COGS (as a proportion of sales) is high while its S,G&A and R&D expenses (as a proportion of sales) are relatively low. This is because Medco Health is a high-volume, low-margin business that requires significant expenditure to generate profits. This emphasis on COGS has hampered Merck's ability to invest in R&D and hence generate organic growth. Therefore, once the spin-off of Medco Health is complete, Merck should be in a position to increase its R&D expenditure significantly, negotiate a greater number of agreements, in-license more drugs for R&D development, and hence improve its organic growth prospects. Growth potential of immune disorders and inflammation portfolio Merck's immune disorders and inflammation portfolio is particularly strong, with a number of marketed blockbuster products. The franchise has demonstrated strong growth over the past few years, a trend that is predicted to continue. Together, four products Vioxx, Arcoxia, Fosamax and Singulair will generate an estimated $9.4 billion in 2007. Merck has two other novel products in development in this area that could also contribute to the longer-term growth of this franchise. Strong Singulair growth driven by allergic rhinitis indication Singulair sales grew by 57% in the fourth quarter of 2002 and grew 35% in 2003 to reach sales of $2 billion for the year. At present it is the most prescribed asthma controller in the US and the second leading product in global total prescription. Merck received FDA approval for Singulair for the relief of symptoms caused by seasonal allergic rhinitis. It is the only brand targeted at both asthma and allergic rhinitis. The company is expected to benefit from patient dissatisfaction with other brands, brand switching and physician familiarity with Singulair as an asthma treatment. Growing sales and marketing force In anticipation of the launches of Cancidas, Invanz, Zetia and Arcoxia, Merck added approximately 1,500 professionals to its sales force, bringing its US sales force up to 6,500. While ensuring that the newly launched products get off to strong starts, this effort will also help drive the growth of Merck's core products, in particular Vioxx, Singulair, Fosamax, Zocor and Cozaar/Hyzaar. For more information visit http://www.researchandmarkets.com/research/6af23e/pharmaceuticals_g Source: Datamonitor |
